When: Price at $344 (lower BB) AND bullish divergence present

Then: Add final 50% of trimmed size

When: Confirmed close above $450 on >2.5M volume held 5+ sessions

Then: Upgrade to Hold, no further trim

REDUCE (Trim 20-30% across $414-$418 zone, hedge 50-75% of residual with $400 puts, trailing stop at 1.5x ATR below 10 EMA)

• Trim 20-30% of ISRG exposure scaled across 2-3 touches of the $414-$418 zone with RSI confirmation, not 30-50% in a single tranche
• Buy 3-month $400 puts on 50-75% of residual position at current implied vol; consider rolling to 6-month protection if vol stays compressed
• Set trailing stop at 1.5x ATR below 10 EMA rather than fixed stop at $397 to avoid whipsaw in v-shaped recovery
• Re-entry in tranches: starter at $384-$396 only if RSI resets to 45-55 and 50 SMA flattens; add on 3 consecutive sessions reclaiming 50 SMA on rising volume; high-conviction add only on reclaim of $450 with flattening 200 SMA
• Monitor inventory line: if inventory growth outpaces revenue growth by more than 1.5x, prepare to reduce further
• At $414.79 with 47.6 trailing P/E, 34 forward P/E, beta of 1.465, and 200 SMA $35 above as declining resistance, the setup favors de-risking now
• Inventory grew 22% YoY to $2.03 billion—a leading indicator of demand absorption risk or channel stuffing that has not been priced into trim thesis
• Tax rate jumped from 12% to 22% in two quarters, creating $300-400M net income swing; forward EPS of $12.09 assumes normalized 12% rate, but at 22% effective rate EPS drops to ~$10.50, making forward P/E closer to 39.5 not 34.3
• Hospital capex pullbacks are budget-cycle events that can compress forward estimates 15-25% in a single quarter—Q2 numbers have not yet reflected moderating U.S. procedure growth flagged by Trefis
• 97% Polymarket probability of zero Fed cuts in 2026 is the base case, not tail risk; long-end yields pushing higher is current trajectory; Zandi's rate damage warning deserves weight
• Homogeneous bullish media during 29% YTD drawdown is contrarian-contrarian behavior, not crowded trade—the crowded trade was at $578 in November 2025

→ vs neutral: HOLD at 47.6 trailing P/E, 34 forward P/E, beta 1.465, price on Bollinger upper band at $417.51 with 200 SMA $35 above as declining resistance is not prudence but negligence—inaction in front of identified multi-factor risk is open-ended drawdown exposure

→ vs aggressive: 30-50% trim into $414-$418 without confirmation of breakdown is front-running conviction not yet proven—price could squeeze 5-8% higher before reversal; selling 50% means chasing re-entry at $445+ if fakeout materializes

→ vs aggressive: $344 re-entry is heroic assumption—lower Bollinger is at $344.82 but 52-week low is $328.57, calling for 17% decline after an 18% rally is directional forecasting, not asymmetric risk management

→ vs aggressive: $397 hard stop at 1.5x ATR invites whipsaw in v-shaped recovery—conservative approach uses trailing stop or widened stop to $384 (VWMA and structural support)

→ vs aggressive: Institutional media bullishness plus retail silence is not crowded trade at $414 after $164 haircut from $578—it is contrarian-contrarian behavior as marginal buyer is institutional allocator re-entering a derisked name, not retail chasing peaks

SELL 25% of position; maintain 50-60% core; hedge residual via covered calls; re-enter on confirmed technical signals

• Trim 25% of ISRG exposure across 2-3 sessions in $412-$418 zone rather than single block trade
• Maintain 50-60% core allocation as fundamentals support ongoing ownership: 18% revenue growth, 150 bps gross margin expansion, 70% YoY free cash flow growth
• Sell covered calls ($430-$440 strikes, 30-45 day expiration) on ~30% of residual position to generate income and avoid long put theta decay
• Re-entry anchored to technical signals, not price targets: starter position at $384-$396 only with RSI 45-55, MACD histogram negative, and 10 EMA flat
• High-conviction add only on confirmed 200 SMA reclaim at $450 with 50 SMA turned up and 3 consecutive sessions of rising volume
• Use structural stop at 50 SMA ($375.32) rather than volatility or hard stops; 50 SMA becomes invalidation level once it flattens and turns up
• Portfolio sizing matters: trim 8% position to 6%, or 4% position to 3%, reflecting concentration risk in a high-beta (1.465) medtech name
• Flag inventory build to $2.03 billion (22% YoY) as leading indicator of demand absorption risk or channel pressure for Q3
• Forward P/E may expand from 34.3 to 38-40 if effective tax rate normalizes at 18-20% instead of consensus 12%, compressing forward EPS to $10.50-$11 from $12.09

→ vs aggressive: The $344 re-entry target is not a re-entry level, it is a wish—no mechanism for what happens if price consolidates between $380-$410 for six months while fundamentals compound, and no contingency for being wrong on short-term tape while right on macro thesis

→ vs aggressive: 30-50% trim built on assumption of $414-$418 rejection as foregone conclusion, but if price chops through $418 on a single session, aggressive analyst converts a 35% gain into a 25% gain while giving up upside if breakout holds

→ vs conservative: Volatility-adjusted stop at 1.5x ATR below 10 EMA puts stop at ~$379, which is too loose and will trigger on first meaningful pullback in V-shaped recovery, creating whipsaw exit at $379 and re-entry at $400+

→ vs conservative: Layered put hedging costs 3-4% of remaining position for 3-month $400 puts on a 47.6 trailing P/E name with 1.465 beta; in low-vol post-rally environment, this converts long-biased position into synthetic short with positive theta bleed

→ vs conservative: No urgency trim language means rejection at $414 may execute faster than rules can react, resulting in trim at $405 instead of $414—treating resistance as zone to scale into rather than level to react to